Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays

Journal of Alzheimer's Disease

Volumn 43, Issue 1, 2014, Pages 183-191

  Lewczuk, Piotr ^a   Lelental, Natalia ^a   Spitzer, Philipp ^a   Maler, Juan Manuel ^a   Kornhuber, Johannes ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

A42 40 ratio; Alzheimer's disease; amyloid ; biomarkers; cerebrospinal fluid; validation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84908700565     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140771     Document Type: Article

References (24)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 263-269.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 270-279.
3. (2009). S3-Leitlinie "Demenzen". http://www.dggpp.de/documents/s3-leitlinie-demenz-kf.pdf
4. European Medicines Agency (2011) Qualification opinion of Alzheimers disease novel methodologies/biomarkers for BMS-708163. http://www.ema.europa.eu/docs/en GB/document library/Regulatory and procedural guideline/2011 /02/WC500102018.pdf
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol 9, 119-128.
6. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
7. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C,Wouters D, BlennowK(2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimers disease diagnosis: A consensus paper from the Alzheimers Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
8. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, OBrien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM,Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimers Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395 e386.
9. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, Frolich L, Schroder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R,Kornhuber J, Lewczuk P (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho- Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101, 1053-1059.
10. Hansson O, ZetterbergH, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimers disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320.
11. Spies PE, Verbeek MM, van Groen T, Claassen JA (2012) Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. Front Biosci (Landmark Ed) 17, 2024-2034.
12. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837-845.
13. Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME (2012) Development and advanced validation of an optimized method for the quantitation of Abeta42 in human cerebrospinal fluid. AAPS J 14, 510-518.
14. Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36, 759-767.
15. Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ,Mondon K, GuilloteauD(2013) Confirmation of the amyloidogenic process in posterior cortical atrophy: Value of the Abeta42/Abeta40 ratio. J Alzheimers Dis 33, 775-780.
16. Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Longitudinal stability of cerebrospinal fluid biomarker levels: Fulfilled requirement for pharmacodynamic markers in Alzheimers disease. J Alzheimers Dis 33, 807-822.
17. Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE (2013) Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimers disease study. Alzheimers Dement 9, 276-283.
18. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L,Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimers disease: A multicenter study. Mol Psychiatry 15, 138-145.
19. Lewczuk P, Popp J, Lelental N, Kolsch H, Maier W, Kornhuber J, Jessen F (2012) Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimers disease. J Alzheimers Dis 28, 119-125.
20. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimers disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
21. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K (2000) Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimers disease patients. Eur Neurol 43, 155-160.
22. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid b proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
23. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimers dementia by CSF Ab42, Ab42/Ab40 ratio and total tau. Neurobiol Aging 25, 273-281.
24. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J,Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloidβ peptides. Clin Chem 52, 332-334.